BridgeBio Pharma is a biotechnology company focused on bridging the gap between genetic research and unmet patient needs. Its pipeline targets Mendelian disorders, precision oncology, and gene therapy, with four programs in late-stage development.
The successful commercialization of Attruby could establish BridgeBio as a key player in the ATTR-CM market, significantly improving its path to profitability.
BridgeBio has historically faced challenges in developing pipeline candidates and bringing them to market.
|
Metric
|
BBIO
|
BNTX
|
ALNY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 28.86 |
Price/Book Value | — | 1.20 | 22.83 |
Price/Sales | 18.20 | 7.77 | 6.68 |
Price/Cash Flow | — | — | 21.53 |
|
Metric
|
BBIO
|
BNTX
|
ALNY
|
|---|---|---|---|
Quick Ratio | 1.09 | 7.71 | 2.79 |
Current Ratio | 1.23 | 7.85 | 3.05 |
Interest Coverage | −2.53 | — | 3.12 |
|
Metric
|
BBIO
|
BNTX
|
ALNY
|
|---|---|---|---|
Return on Assets (Normalized) | −50.11% | −5.73% | 22.09% |
Return on Equity (Normalized) | — | −6.58% | 149.53% |
Return on Invested Capital (Normalized) | −13,484.19% | −6.97% | 63.06% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|fzQxsPb | LOCK|#Cyn^ | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|bZ<&fd | LOCK|jY>y | $76B | |||
| Moderna Inc
MRNA
| LOCK|?cJ&^jN | LOCK|vz | $75B | |||
| argenx SE ADR
ARGX
| LOCK|t&WyYF | LOCK|qG | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Tq$P#L% | LOCK|qw | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|kc!G!Y | LOCK|vcQF? | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|G>Zm&MqH | LOCK|Q!X# | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|$WZ&<dS | LOCK|Tqq | $24B | |||
| Incyte Corp
INCY
| LOCK|%$@m&?Y | LOCK|&n | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Rz%Ygc | LOCK|y> | $15B |
United States